ProstaLund Revenue and Competitors
Estimated Revenue & Valuation
- ProstaLund's estimated annual revenue is currently $6.8M per year.
- ProstaLund's estimated revenue per employee is $251,000
Employee Data
- ProstaLund has 27 Employees.
- ProstaLund grew their employee count by 0% last year.
ProstaLund's People
| Name | Title | Email/Phone |
|---|---|---|
1 | QA Manager | Reveal Email/Phone |
ProstaLund Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is ProstaLund?
ProstaLund is a Swedish medtech company and a leading developer and manufacturer of innovative urological devices and treatments. CoreTherm is a patented Thermotherapy treatment method for BPH which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide.
keywords:N/A
N/A
Total Funding
27
Number of Employees
$6.8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ProstaLund News
... Freja EID, Goodbye Kansas, I-Tech, Karo Pharma, Lexington, Lifeclean, Lipidor, Magle Chemoswed, Prostalund, Qlife, Speqta, Westpay.
Prostalund har tecknat ett avtal med Capio Specialistcenter om engångsmaterial till Coretherm-behandlingar. Publicerad: 26 april 2022, 16:08...
ProstaLund organized a national Experience Meeting for CoreTherm® users in Stockholm from 31 March to 1 April. The participants' evaluation...
Other Companies in Lund
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 28 | 8% | N/A |
#2 | $4.3M | 28 | -35% | N/A |
#3 | $2.8M | 29 | -6% | N/A |
#4 | $4.1M | 29 | 190% | N/A |
#5 | $2.1M | 29 | 16% | N/A |